Asimov achieves 10x improvement in lentiviral production, launches new stable cell line development service. 

  • Stable lentiviral (LV) cell line development service achieves unconcentrated titers >1E9 TU/mL for therapeutic transgenes. 
  • Fully stable cell lines have all viral genes and transgene stably integrated, enabling biomanufacturing scalability and a more robust production process. 
  • Transfection-free lentiviral manufacturing eliminates GMP plasmid cost and reduces supply chain risk for cell and gene therapy developers. 

Boston, Massachusetts, 29 April 2024: Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the expansion of its LV Edge System with the launch of a fully stable cell line development service.

There are now two ways for customers to access Asimov’s cell line technology to minimize cost and manufacturing risk, depending on their needs:

  1. The LV Edge Packaging System, launched earlier this year, which enables a single plasmid transfection that achieves E8 TU/mL.
  2. The new, fully-stable LV Edge Producer cell line development service, which generates clones that achieve E9 TU/mL with no transient transfection required.

The LV Edge Producer System completely eliminates GMP plasmid cost and greatly reduces process complexity and variability by stably integrating all the genes for lentiviral production into the host cell.

Current processes for lentiviral production are inherently scale-limited and variable due to the need for multi-plasmid transient transfection. Furthermore, the reliance on GMP plasmids and transfection reagents substantially increases costs and introduces supply chain and product variability risks. The development of a fully stable cell line technology enables scalable, reproducible and low-cost production of lentivirus, which will unlock applications for larger therapeutic indications. 

LV Edge Producer Cell Lines achieve E9 TU/mL unconcentrated lentiviral titers for clinically relevant chimeric antigen receptor (CAR) transgenes. The service takes less than 6 months from sequence transfer to a stable, clonal cell line and is performed in Asimov’s Boston cell line development facility. 

Alec Nielsen, Co-founder and CEO of Asimov commented: “We developed the LV Edge System to address the rising demand for scalable lentiviral production. Today’s launch expands the LV Edge portfolio, allowing therapeutic developers to choose between an off-the-shelf single plasmid packaging system they can use in their own lab, or a plasmid free cell line development service performed by Asimov, achieving industry-leading titers in both cases. These advances were made possible by integrating mammalian synthetic biology, computational models, and our design software (Kernel), furthering our goal of democratizing state-of-the-art genetic design capabilities to our partners.”

For more information on the LV Edge System, please visit: www.asimov.com/LV

Highlights

  • Virtual Private Network (VPN): Users connect to the cluster, provide some credentials and are then able to access internal tools.
  • Single Sign-On: A tool like Kerberos allows you to use the same account across various components.
  • Home-grown user accounts: You implement an authentication system and users have a separate username/password for your computing infrastructure.

Asimov, the synthetic biology company building a full-stack platform to program living cells, announced today it has been awarded a contract as part of the Defense Advanced Research Projects Agency (DARPA) Automating Scientific Knowledge Extraction (ASKE) opportunity.

Through ASKE, Asimov will work to develop a physics-based artificial intelligence (AI) design engine for biology. The goal of the initiative is to improve the reliability of programming complex cellular behaviors.

“To achieve truly predictive engineering of biology, we require dramatic advances in computer-aided design. Machine learning will be critical to bridge genome-scale experimental data with computational models that accurately capture the underlying biophysics. As genetically engineered systems grow in complexity, they become difficult for humans to design and understand. For simple genetic systems with only a couple of genes, synthetic biologists typically use high-throughput screening and basic optimization algorithms. But to engineer more complex applications in health, materials, and manufacturing, we need radically new algorithms to intelligently design the DNA and simulate cell behavior.”

Alec Nielsen, Phd, Asimov CEO
Over the past 50 years, DARPA has been a world leader in spurring innovation across the field of AI, including statistical-learning and rule-based approaches. We are proud to work with DARPA to advance the state-of-the-art in AI-assisted genetic engineering.

Asimov’s founders previously built a hybrid genetic engineering and computer-aided design platform called Cello to program logic circuit behaviors in cells. The ASKE opportunity will seek to support an ambitious expansion in the types of biological behaviors that can be engineered.

Asimov’s approach will leverage “multi-omics” cellular measurements, structured biological metadata, and novel AI architectures that combine deep learning, reinforcement learning, and mechanistic modeling. Over the past year, the company has ramped up hiring in experimental synthetic biology, machine learning, and data science to accelerate development of their genetic design platform.

Highlights

Headering 3

DARPA recently announced a multi-year investment of $2B into innovative artificial intelligence research called the AI Next campaign. A part of this wide-ranging AI strategy is DARPA’s Artificial Intelligence Exploration program, which was developed to help expeditiously move pioneering AI research from idea to exploration in fewer than 90 days. DARPA’s ASKE opportunity is part of this program and is focused on developing AI technologies that can reason over rich models of complex systems.

“Over the past 50 years, DARPA has been a world leader in spurring innovation across the field of AI, including statistical-learning and rule-based approaches. We are proud to work with DARPA to advance the state-of-the-art in AI-assisted genetic engineering.”

Alec Nielsen, PhD, Asimov CEO
This is some text inside of a div block. Great

Related posts

Blog
announcement
science & technology
Asimov and RevOpsis Therapeutics Sign Licensing Agreement for High Titer Multispecific-Expressing Cell Line

Asimov and RevOpsis Therapeutics Sign Licensing Agreement for High Titer Multispecific-Expressing Cell Line

Asimov and RevOpsis Therapeutics Sign Licensing Agreement for High Titer Multispecific-Expressing Cell Line

November 19, 2024
November 19, 2024
Blog
announcement
science & technology
Asimov launches AAV Edge, a suite of AI models, host cells, and genetic tools for end-to-end gene therapy development

Asimov launches AAV Edge, a suite of AI models, host cells, and genetic tools for end-to-end gene therapy development

Asimov launches AAV Edge, a suite of AI models, host cells, and genetic tools for end-to-end gene therapy development

September 18, 2024
September 18, 2024
Blog
announcement
science & technology
Asimov introduces its AI-driven 4th generation CHO Edge System with increased titer guarantee

Asimov introduces its AI-driven 4th generation CHO Edge System with increased titer guarantee

Asimov introduces its AI-driven 4th generation CHO Edge System with increased titer guarantee

July 30, 2024
July 30, 2024
let’s CONNECT

Excited by the intersection of biology, engineering,
and machine learning?
Get in touch.

Asimov team at their Boston office
Illustration of a white blood cell